Lucid Diagnostics Inc.
Lucid Diagnostics Inc. (LUCD) Stock Overview
Explore Lucid Diagnostics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
119M
P/E Ratio
-0.00
EPS (TTM)
$-1.17
ROE
26.96%
LUCD Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Lucid Diagnostics Inc. (LUCD) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.65.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.00 and a market capitalization of 119M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Lishan Aklog
72
One Grand Central Place, New York City, NY
2021